natgillin/translations-raw huggingface dataset:
Talk to your doctor.
Posvetujte se s svojim zdravnikom.
Repaglinide is eliminated rapidly within 4 - 6 hours from the blood.
Repaglinid se iz krvi hitro izloči, v 4 do 6 urah.
Enyglid has no or negligible influence on the ability to drive and use machines but may cause hypoglycaemia.
Zdravilo Enyglid nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji, vendar pa lahko povzroči hipoglikemijo.
- Diabetes mellitus type 1, C-peptide negative.
- Sladkorna bolezen tipa 1 (na C-peptid negativna).
The total maximum daily dose should not exceed 16 mg.
Skupni največji dnevni odmerek ne sme preseči 16 mg.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Special patient groups
Posebne skupine bolnikov
Do not use this medicine after the expiry date which is stated on the blister and outer carton.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli.
The plasma elimination half-life is approximately one hour.
Plazemski razpolovni čas izločanja znaša približno 1 uro.
Repaglinide has been given with weekly escalating doses from 4 - 20 mg four times daily in a 6 week period.
Repaglinid so uporabljali v tedensko naraščajočih odmerkih od 4 do 20 mg štirikrat na dan 6 tednov.
At such times, it may be necessary to discontinue repaglinide and treat with insulin on a temporary basis.
V takšnih primerih utegne biti potrebna prekinitev uporabe repaglinida in začasno zdravljenje z insulinom.
In addition to the usual self-monitoring by the patient of blood and/or urinary glucose, the patient's blood glucose must be monitored periodically by the physician to determine the minimum effective dose for the patient.
Poleg običajne samokontrole glukoze v krvi in/ali urinu, ki jo izvaja bolnik, mora bolnikovo glukozo v krvi redno nadzirati tudi zdravnik, da določi za bolnika najmanjši učinkoviti odmerek.
Talk to your doctor if any of the above applies to you.
Obvestite zdravnika, če se karkoli od naštetega nanaša na vas.
This may be due to progression of the severity of the diabetes or to diminished responsiveness to the medicinal product.
To je lahko posledica napredovanja sladkorne bolezni ali zmanjšanja odzivnosti na zdravilo.
The occurrence of such reactions depends on individual factors, such as dietary habits, dosage, exercise and stress.
Pojavnost takšnih reakcij je odvisna od individualnih dejavnikov, kot so prehranske navade, uporabljen odmerek, telesna dejavnost in stres.
Changes in blood glucose levels have been known to result in transient visual disturbances, especially at the commencement of treatment.
Znano je, da spremembe v koncentraciji glukoze v krvi povzročijo prehodne motnje vida, še posebej na začetku zdravljenja.
- Hypersensitivity to repaglinide or to any of the excipients listed in section 6.1.
- Preobčutljivost na repaglinid ali katero koli pomožno snov, navedeno v poglavju 6.1.
Repaglinide is a short-acting oral secretagogue.
Repaglinid je nov kratkotrajno delujoči peroralni sekretagog.
Watch for signs of a hypo.
Bodite pozorni na znake hipoglikemije.
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Germany
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Nemčija
In this case, the dosage of metformin should be maintained and repaglinide administered concomitantly.
V tem primeru je treba odmerjanje metformina ohraniti in sočasno uporabljati še repaglinid.
This resulted in a blood glucose-lowering effect throughout the meal period.
To je povzročilo znižanje glukoze v krvi v celotnem obdobju obroka.
When repaglinide is used together with other medicinal products that are mainly secreted by the bile, like repaglinide, any potential interaction should be considered.
Če se repaglinid uporablja skupaj z drugimi zdravili, ki se izločajo predvsem z žolčem, tako kot repaglinid, je treba upoštevati morebitne interakcije.
• if you have liver problems.
- če imate težave z ledvicami.
Clinical study results have shown that repaglinide is optimally dosed in relation to main meals (preprandial dosing).
Izsledki kliničnih študij kažejo, da je repaglinid optimalno uporabiti ob glavnih obrokih (predprandialno odmerjanje).
Generalised hypersensitivity reactions (e.g. anaphylactic reaction), or immunological reactions such as vasculitis.
Generalizirane preobčutljivostne reakcije (npr. anafilaktična reakcija) ali imunološke reakcije, npr. vaskulitis.
Swallow the tablets with a glass of water immediately before or up to 30 minutes before each main meal.
Tablete vzemite s kozarcem vode tik pred ali do 30 minut pred vsakim glavnim obrokom.
The elevated insulin levels did not persist beyond the time of the meal challenge.
Zvečana koncentracija inzulina ni trajala dlje izziv z obrokom.
Repaglinide should be avoided during pregnancy.
Med nosečnostjo se je treba uporabi repaglinida izogibati.
Allergy is very rare (may affect up to 1 in 10,000 people).
Alergija je zelo redka (lahko se pojavi pri največ 1 od 10.000 bolnikov).
A small fraction (less than 8%) of the administered dose appears in the urine, primarily as metabolites.
Manjši del (manj kot 8 %) uporabljenega odmerka se izloči z urinom, v glavnem v obliki presnovkov.
Elderly No clinical studies have been conducted in patients >75 years of age.
Starostniki Klinične študije pri bolnikih, starejših od 75 let, niso bile izvedene.
Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they must turn you on your side and get medical help straight away.
Ljudem povejte, da ste sladkorni bolnik in naj vas v primeru, če se onesvestite (izgubite zavest), položijo na bok in nemudoma poiščejo zdravniško pomoč.
If severe hypoglycaemia is not treated, it can cause brain damage (temporary or permanent) and even death.
- Dolgotrajna nezdravljena huda hipoglikemija lahko povzroči (prehodno ali trajno) okvaro možganov in celo smrt.
Combination treatment with metformin is associated with an increased risk of hypoglycaemia.
Kombinirano zdravljenje z metforminom spremlja večje tveganje za pojav hipoglikemije.
Enyglid may not be suitable for you.
Zdravljenje z zdravilom Enyglid pri vas morda ni primerno.
Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i.e. primary failure) and to detect loss of adequate blood-glucose lowering response after an initial period of effectiveness (i.e. secondary failure).
Redno spremljanje je potrebno zato, da bi odkrili nezadostno znižanje glukoze v krvi ob priporočenem največjem odmerka (tj. primarna odpoved), ali nezadostno znižanje glukoze po uvodnem obdobju učinkovitosti (tj. sekundarna odpoved).
Your diabetes may get worse.
Urejenost sladkorne bolezni se lahko poslabša.
Substances that inhibit OATP1B1 may likewise have the potential to increase plasma concentrations of repaglinide, as has been shown for ciclosporin (see below).
Učinkovine, ki zavirajo OATP1B1, lahko morda povečajo koncentracijo repaglinida v plazmi zvišajo podobno, kot je ugotovljeno za ciklosporin (glejte v nadaljevanju).
This depolarises the β-cell and leads to an opening of the calcium channels.
To depolarizira celico β in povzroči odprtje kalcijevih kanalov.
* see section Description of selected adverse reactions below
* glejte poglavje Opis izbranih neželenih učinkov v nadaljevanju
This phenomenon is known as secondary failure, to distinguish it from primary failure, where the medicinal product is ineffective in an individual patient when first given.
Pojav je poznan kot sekundarna odpoved, za razliko od primarne odpovedi, pri kateri je zdravilo neučinkovito, že ko ga bolnik vzame prvič.
One epidemiological study suggested an increased risk of acute coronary syndrome in repaglinide treated patients as compared to sulfonylurea treated patients (see sections 4.4 and 4.8).
Ena epidemiološka študija je nakazala večje tveganje za razvoj akutnega koronarnega sindroma pri bolnikih, zdravljenih z repaglinidom, v primerjavi z bolniki, zdravljenimi z derivati sulfonilsečnine (glejte poglavji 4.4 in 4.8).
- Concomitant use of gemfibrozil (see section 4.5).
- Sočasna uporaba gemfibrozila (glejte poglavje 4.5).
Rare (may affect up to 1 in 1,000 people): • Acute coronary syndrome (but it may not be due to the medicine).
Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) - akutni koronarni sindrom (ki pa ni nujno povezan z uporabo zdravila)
More severe hypoglycaemia with seizure, loss of consciousness or coma should be treated with intravenous glucose.
Hujšo hipoglikemijo s krči, izgubo zavesti ali komo je treba zdraviti z intravensko aplikacijo glukoze.
Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1).
Podatki pridobljeni in vitro kažejo, da je repaglinid substrat aktivnega prevzema v jetrih (transportna beljakovina organskih anionov OATP1B1).
Repaglinide should be taken before main meals (i.e. preprandially).
Bolnik mora repaglinid vzeti pred glavnimi obroki (tj. predprandialno).
30 tablets 60 tablets 90 tablets 120 tablets 180 tablets 270 tablets 360 tablets
30 tablet 60 tablet 90 tablet 120 tablet 180 tablet 270 tablet 360 tablet
Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal (i.e. preprandially 2, 3, or 4 meals a day).
Odmerek se običajno vzame 15 minut pred obrokom, vendar pa lahko čas zaužitja sega od 30 minut pred obrokom do tik pred njim (tj. predprandialno, v primeru 2, 3 ali 4 obrokov na dan).
Do not take a double dose to make up for a forgotten tablet.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Trials investigating the combination with other insulin secretagogues have not been performed.
Preskušanja, ki bi proučila kombinacijo z drugimi sekretagogi inzulina, niso bila izvedena.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
The maximum recommended daily dose is 16 mg.
Največji priporočeni dnevni odmerek je 16 mg.
No interaction studies have been performed in children and adolescents.
Študij medsebojnega delovanja z drugimi zdravili pri otrocih in mladostnikih niso izvedli.
In type 2 diabetic patients, the insulinotropic response to a meal occurred within 30 minutes after an oral dose of repaglinide.
Pri bolnikih s sladkorno boleznijo tipa 2 se je inzulinotropni odziv na obrok pojavil v 30 minutah po peroralnem odmerku repaglinida.
Hypoglycaemic reactions are generally mild/moderate but may occasionally develop into hypoglycaemic unconsciousness or coma.
Hipoglikemične reakcije so običajno blage/zmerne, v posameznih primerih pa lahko napredujejo do hipoglikemične nezavesti ali kome.
Boxes of 30, 60, 90, 120, 180, 270 or 360 tablets in blisters are available.
Na voljo so škatle s 30, 60, 90, 120, 180, 270 ali 360 tabletami v pretisnih omotih.
Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
Zdravljenje je treba uvesti kot dodatek k dieti in telesni dejavnosti za znižanje koncentracije glukoze v krvi ob obrokih.
Repaglinide is given preprandially and is titrated individually to optimise glycaemic control.
Repaglinid se uporablja predprandialno in ga je treba za optimiranje urejenosti glikemije individualno prilagoditi.
Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka (pankreas) ne tvori dovolj inzulina, da bi uravnal koncentracijo sladkorja v krvi ali pa se telo ne odziva normalno na inzulin, ki ga sam proizvaja.
In very rare cases, severe hepatic dysfunction has been reported.
V zelo redkih primerih so poročali o pojavu zelo hudih motenj delovanja jeter.
Should these symptoms occur, adequate action should be taken to correct the low blood glucose (oral carbohydrates).
Če se ti simptomi pojavijo, je treba ustrezno ukrepati, da bi odpravili nizko koncentracijo glukoze v krvi (zaužitje ogljikovih hidratov).
Combination with Neutral Protamine Hagedorn (NPH) insulin or thiazolidinediones
Kombinacija z inzulinom NPH (Neutral Protamine Hagedorn) ali s tiazolidindioni
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Nemčija KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Hrvaška
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose adjustment which should be based on carefully monitored blood glucose concentrations at both initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of rifampicin where the inductive effect of rifampicin is no longer present.
Zaradi sočasne uporabe rifampicina in repaglinida lahko torej pride do potrebe po prilagajanju odmerka repaglinida, ki mora temeljiti na skrbnem nadziranju vrednosti glukoze v krvi, tako ob uvedbi zdravljenja z rifampicinom (akutna inhibicija) kot ob nadaljnjevanju (mešana inhibicija in indukcija) ter ukinitvi zdravljenja (samo indukcija) in še približno do dva tedna po ukinitvi rifampicina, ko indukcijski učinek rifampicina izzveni.
The warning signs of a hypo may come on suddenly and can include: cold sweat, cool pale skin, headache, rapid heart beat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in concentrating.
Opozorilni znaki hipe se lahko pojavijo nenadoma in lahko vključujejo: hladno znojenje, hladno in bledo kožo, glavobol, hitro bitje srca, občutek slabosti, hudo lakoto, prehodne spremembe vida, zaspanost, nenavadno utrujenost in šibkost, živčnost ali tresenje, občutek tesnobe, občutek zmedenosti in težave s koncentracijo.
Contact a doctor immediately.
Nemudoma se posvetujte s svojim zdravnikom.
Short-term administration of repaglinide may be sufficient during periods of transient loss of control in Type 2 diabetic patients usually controlled well on diet.
Kratkotrajna uporaba repaglinida lahko zadošča v obdobjih prehodne izgube urejenosti sladkorne bolezni tipa 2 pri bolnikih, pri katerih je bolezen ponavadi dobro urejena z dieto.
What Enyglid is and what it is used for
Kaj je zdravilo Enyglid in za kaj ga uporabljamo
The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 people (see If you get a hypo in section 2).
Hipoglikemija je najpogostejši neželeni učinek, ki se lahko pojavi pri največ 1 od 10 bolnikov (glejte odstavek V primeru pojava hipe v poglavju 2).
Blister pack (OPA/Alu/PVC-Alu): 30, 60, 90, 120, 180, 270 and 360 tablets in the box.
Pretisni omot (OPA/Al/PVC-Al): 30, 60, 90, 120, 180, 270 in 360 tablet v škatli.
The blood glucose-lowering effect of oral hypoglycaemic medicinal products decreases in many patients over time.
Učinkovitost zniževanja glukoze v krvi s peroralnimi antidiabetiki se pri številnih bolnikih sčasoma zmanjša.
The most frequently reported adverse reactions are changes in blood glucose levels, i.e. hypoglycaemia.
Neželeni učinki, o katerih so poročali najpogosteje, so spremembe vrednosti glukoze v krvi, kot je hipoglikemija.
A number of medicinal products are known to influence repaglinide metabolism, possible interactions should therefore be taken into account by the physician:
Na presnovo repaglinida lahko vplivajo številna zdravila, zato mora zdravnik upoštevati možne interakcije.
Alcohol can change the ability of Enyglid to reduce the blood sugar.
Alkohol lahko spremeni sposobnost zdravila Enyglid, da zniža vrednost krvnega sladkorja.
As hypoglycaemia in this study was avoided through increased calorie intake, a relative overdose may result in an exaggerated glucose lowering effect with development of hypoglycaemic symptoms (dizziness, sweating, tremor, headache etc.).
Ker so se hipoglikemiji v tej študiji izognili z večjim kaloričnim vnosom; lahko relativno preveliko odmerjanje povzroči čezmerno znižanje glukoze in pojav simptomov hipoglikemije (omotica, znojenje, tremor, glavobol, ipd.).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, da morajo upoštevati ustrezne varnostne ukrepe, da med upravljanjem vozila ne bi prišlo do hipoglikemije.
Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: - Common (1/100 to <1/10) - Uncommon (1/1,000 to <1/100) - Rare (1/10,000 to <1/1,000) - Very rare (<1/10,000) - Not known (cannot be estimated from the available data)
Pogostnost je opredeljena kot: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Enyglid with alcohol
Zdravila Enyglid skupaj z alkoholom
When repaglinide was given 24 hours after the last rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Če so osebe repaglinid prejele 24 ur po zadnjem odmerku rifampicina, so opazili 80 % zmanjšanje vrednosti AUC repaglinida (učinek samo indukcije).
What you need to know before you take Enyglid).
Kaj morate vedeti, preden boste vzeli zdravilo Enyglid).
Repaglinide pharmacokinetics are characterised by a mean absolute bioavailability of 63% (CV 11%).
Za farmakokinetiko repaglinida je značilna 63-% povprečna absolutna biološka uporabnost (koeficient variabilnosti je 11 %).
Symptoms such as swelling, difficulty in breathing, rapid heartbeat, feeling dizzy and sweating could be signs of anaphylactic reaction.
Simptomi, kot so otekanje, težave z dihanjem, pospešeno bitje srca, omotica in znojenje, so lahko znaki anafilaktične reakcije.
Pharmaco-therapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX02
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, drugi antidiabetiki razen insulinov, oznaka ATC: A10BX02.
The amount of Enyglid, food or exercise may need to be adjusted.
Morda bo treba prilagoditi odmerek zdravila Enyglid, količino zaužite hrane ali stopnjo telesne dejavnosti.
The use of repaglinide might be associated with an increased incidence of acute coronary syndrome (e.g. myocardial infarction), see sections 4.8 and 5.1.
Uporabo repaglinida lahko spremlja večja pojavnost akutnega koronarnega sindroma (npr. miokardni infarkt), glejte poglavji 4.8 in 5.1.
If your blood sugar is low or you feel a hypo coming on eat glucose tablets or a high sugar snack or drink, then rest.
Če se vam krvni sladkor preveč zniža ali začutite pojav hipe, zaužijte tablete glukoze ali prigrizek z veliko sladkorja in nato počivajte.
Repaglinide should only be prescribed if poor blood glucose control and symptoms of diabetes persist despite adequate attempts at dieting, exercise and weight reduction.
Repaglinid se sme predpisati le, če se slaba urejenost glikemije in simptomi sladkorne bolezni nadaljujejo kljub ustrezni dieti, telesni dejavnosti in zmanjšanju telesne mase.
Doses are usually taken within 15 minutes of the meal, but the time may vary from immediately preceding the meal to as long as 30 minutes before the meal.
Odmerek se običajno vzame v 15 minutah pred obrokom, vendar pa se lahko ta čas giblje v razponu od tik pred obrokom do 30 minut pred njim.
Less than 1% of repaglinide is recovered in faeces.
Z blatom se izloči manj kot 1 % repaglinida.
After reaching a maximum, the plasma level decreases rapidly.
Potem ko doseže največjo vrednost, se plazemska koncentracija hitro zmanjša.
Repaglinide acts through a distinct binding site with a short action on the β-cells.
Repaglinid deluje prek posebnega vezavnega mesta s kratkim delovanjem na celice .
Other medicines and Enyglid
Druga zdravila in zdravilo Enyglid
The concomitant use of gemfibrozil and repaglinide is contraindicated (see section 4.3).
Sočasna uporaba gemfibrozila in repaglinida je tako kontraindicirana (glejte poglavje 4.3).
There is no reason to suspect cross-allergenicity with sulphonylurea due to the difference in chemical structure.
Navzkrižne alergenosti z derivati sulfonilsečnine zaradi različne kemične zgradbe ni pričakovati.
• The normal starting dose is 0.5 mg before each main meal.
- Običajni začetni odmerek je 0,5 mg tik pred vsakim glavnim obrokom.
There are no studies of repaglinide in pregnant women.
Študije o uporabi repaglinida pri nosečnicah niso bile izvedene.
Use of repaglinide in case of secondary failure to insulin secretagogues has not been investigated in clinical trials.
Uporaba repaglinida v primerih sekundarne odpovedi sekretagogov inzulina v kliničnih preskušanjih ni bila raziskana.
Repaglinide closes ATP-dependent potassium channels in the β-cell membrane via a target protein different from other secretagogues.
Repaglinid v membrani celic β zapre od ATP-ja odvisne kalijeve kanalčke, in sicer prek tarčne beljakovine, ki pa ni ista kot pri ostalih sekretagogih.
When these medications are administered to or withdrawn from a patient receiving repaglinide, the patient should be observed closely for changes in glycaemic control.
Ob uvedbi ali ukinitvi zdravljenja s temi zdravili je bolnika, ki jemlje repaglinid, treba skrbno nadzirati, da bi odkrili spremembe v urejenosti glikemije.
Patients receiving other oral hypoglycaemic medicinal products Patients can be transferred directly from other oral hypoglycaemic medicinal products to repaglinide.
Bolniki, ki se zdravijo z drugimi peroralnimi antidiabetiki Bolnike je mogoče na repaglinid prevesti neposredno z drugih peroralnih antidiabetikov.
Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
Uporaba repaglinida je indicirana pri odraslih bolnikih s sladkorno boleznijo tipa 2, pri katerih hiperglikemije ni več mogoče zadovoljivo obvladovati z dieto, zmanjšanjem telesne mase in s telesno dejavnostjo.
If you have a hypo that makes you pass out, or a lot of hypos, talk to your doctor.
- Če doživite hipo, zaradi katere se onesvestite, ali doživljate veliko hip, se posvetujte s svojim zdravnikom.
If patients are transferred from another oral hypoglycaemic medicinal product, the recommended starting dose is 1 mg.
Če bolnik preide na repaglinid z drugega peroralnega antidiabetika, je priporočeni začetni odmerek repaglinida 1 mg.
If you forget to take Enyglid
Če ste pozabili vzeti zdravilo Enyglid
Enyglid is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose).
Zdravilna učinkovina zdravila Enyglid je repaglinid, ki trebušni slinavki pomaga, da tvori več inzulina in tako znižuje vrednost krvnega sladkorja (glukoze).
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the pharmacokinetics of repaglinide has been studied in healthy subjects.
Vpliv ketokonazola (prototip močnega in kompetitivnega zaviralca CYP3A4) na farmakokinetiko repaglinida so raziskovali pri zdravih prostovoljcih.
Enyglid has been shown to lower the blood sugar, which helps to prevent complications from your diabetes.
Zdravilo Enyglid dokazano znižuje vrednost krvnega sladkorja, kar pomaga preprečiti razvoj zapletov zaradi sladkorne bolezni.